Objective To analyze the expression of leucine rich repeat protein 8A(LRRC8A)and methyltransferase like protein 14(METTL14)in cervical cancer(CC)and explore their clinical significance.Methods One hundred and thirty-eight patients with CC who underwent diagnosis and treatment from February 2019 to March 2021 were selected.Immuno-histochemistry and real-time fluorescence quantitative PCRwere used to detect the expression of LRRC8A and METTL14 in CC.K-M survival curve were drew and the differences between the curves were compared by Log Rank test.The prognos-tic factors affecting CC were screen by COX regression model.Results The expression levels of LRRC8A mRNA and METTL14 mRNA in CC cancer tissues were higher than those in adjacent tissues(t/P=44.520/＜0.001,42.352/＜0.001).The positive rates of LRRC8A protein and METTL14 protein in cancer tissues were higher than those in adjacent tissues(all P＜0.001).The positivity rates ofLRRC8A and METTL14 proteins in cancer tissues of patients with FIGO staging Ⅰ B2-ⅡA and lymph node metastasis were higher(P＜0.05).The 3-year overall survival(OS)of LRRC8A positive and negative groups were 71.43％(70/98)and 90.00％(36/40),respectively;The 3-year OS of METTL14 positive and negative groups were 70.65％(65/92)and 89.13％(41/46),respectively.Log Rank test showed that the overall 3-year survival rate of the LRRC8A positive group and the METTL14 positive group was lower than that of the LRRC8A negative group and the METTL14 negative group,with statistically significant differences(Log Rank x2=5.065,7.690,P=0.023,0.006).LRRC8A positive and METTL14 positive groups,as well as FIGO staging stages ⅠB2-ⅡA,were independent risk factors[OR(95％CI)=1.679(1.301-2.166),1.429(1.156-1.766),1.713(1.187-2.471)].Conclusion Elevated expression of LRRC8A and METTL14 in CC are associated with FIGO staging and lymph node metastasis in CC patients,and are biomarkers for signal assessment of poor survival prognosis in CC patients.
Cervical cancerRich in leucine repeat protein 8AMethyltransferase like protein 14Prognosis
维普
万方数据
